TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION IN CLL CELLS

被引：0
|
作者：
Kotaskova, J. [1 ,2 ,3 ]
Pavlova, S. [1 ,2 ,3 ]
Plevova, K. [1 ,2 ,3 ]
Malcikova, J. [1 ,2 ,3 ]
Stehlikova, O. [1 ,2 ]
Poppova, L. [1 ,2 ]
Kockova, H. [1 ,2 ]
Doubek, M. [2 ,3 ,4 ]
Bryja, V. [5 ]
Pospisilova, S. [1 ,2 ,3 ]
机构：
[1] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, CMBGT, Brno, Czech Republic
[2] Masaryk Univ, Fac Med, Brno, Czech Republic
[3] Masaryk Univ, Cent European Inst Technol CEITEC, Brno, Czech Republic
[4] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic
[5] Masaryk Univ, Fac Sci, Inst Expt Biol, Brno, Czech Republic
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1009
引用
收藏
页码：414 / 414
页数：1
相关论文
共 50 条
  • [1] ROR1 expression is not a unique marker of CLL
    Barna, Gabor
    Mihalik, Rudolf
    Timar, Botond
    Toemboel, Judit
    Csende, Zsolt
    Sebestyen, Anna
    Boedoer, Csaba
    Csernus, Balazs
    Reiniger, Lilla
    Petak, Istvan
    Matolcsy, Andras
    [J]. HEMATOLOGICAL ONCOLOGY, 2011, 29 (01) : 17 - 21
  • [2] ROR1 EXPRESSION IS NOT A UNIQUE MARKER OF CLL
    Barna, Gabor
    Mihalik, Rudolf
    Timar, Botond
    Csende, Zsolt
    Sebestyen, Anna
    Toemboel, Judit
    Boedoer, Csaba
    Csernus, Balazs
    Matolcsy, Andras
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2010, 78B (06) : 436 - 436
  • [3] Design and structural modification of ROR1 CAR T-cells as a treatment for CLL
    Davies, David Marc
    Moscosso, Solange Parades
    Gohil, Satyen
    Pule, Martin
    Nathwani, Amit
    [J]. HUMAN GENE THERAPY, 2014, 25 (05) : A17 - A18
  • [4] Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells
    Choudhury, Aniruddha
    Derkow, Katja
    Daneshmanesh, Amir Hossein
    Mikaelsson, Eva
    Kiaii, Shahryar
    Kokhaei, Parviz
    Osterborg, Anders
    Mellstedt, Hakan
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2010, 151 (04) : 327 - 335
  • [5] Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells
    Dave, Zankruti
    Blanarova, Olga Vondalova
    Cada, Stepan
    Janovska, Pavlina
    Zezula, Nikodem
    Behal, Martin
    Hanakova, Katerina
    Ganji, Sri Ranjani
    Krejci, Pavel
    Gomoryova, Kristina
    Peschelova, Helena
    Smida, Michal
    Zdrahal, Zbynek
    Pavlova, Sarka
    Kotaskova, Jana
    Pospisilova, Sarka
    Bryja, Vitezslav
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
  • [6] ROR1 Isoforms Are Constitutively Phosphorylated in Chronic Lympho cytic Leukemia (CLL) - a Survival Factor for CLL Cells
    Mellstedt, Hakan
    Hojjat-Farsangi, Mohammad
    Mansouri, Ladan
    Osterborg, Anders
    Rabbani, Hodjattallah
    [J]. BLOOD, 2011, 118 (21) : 775 - 776
  • [7] ROR1 and ROR2 expression in pancreatic cancer
    Dongli Liu
    George Sharbeen
    Phoebe Phillips
    Caroline E. Ford
    [J]. BMC Cancer, 21
  • [8] Molecular mechanism regulating expression of Ror1 in GSCs and the role of Ror1 in maintaining their stemness
    Ishikawa, Tomohiro
    Endo, Mitsuharu
    Tanaka, Kazuhiro
    Nagashima, Hiroaki
    Sasayama, Takashi
    Minami, Yasuhiro
    [J]. CANCER SCIENCE, 2023, 114 : 1141 - 1141
  • [9] ROR1 and ROR2 expression in pancreatic cancer
    Liu, Dongli
    Sharbeen, George
    Phillips, Phoebe
    Ford, Caroline E.
    [J]. BMC CANCER, 2021, 21 (01)
  • [10] The Tyrosine Kinase Receptor ROR1 Is Constitutively Phosphorylated in Chronic Lymphocytic Leukemia (CLL) Cells
    Hojjat-Farsangi, Mohammad
    Khan, Abdul Salam
    Daneshmanesh, Amir Hossein
    Moshfegh, Ali
    Sandin, Asa
    Mansouri, Ladan
    Palma, Marzia
    Lundin, Jeanette
    Osterborg, Anders
    Mellstedt, Hakan
    [J]. PLOS ONE, 2013, 8 (10):
12345